Gene Therapy(FT-003) for Wet AMD — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Gene Therapy(FT-003) for Wet AMD — Stella

Home/Neovascular Age-related Macular Degeneration/

View on ClinicalTrials.gov

Recruiting

Back to Neovascular Age-related Macular Degeneration trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Tianjin Medical University Eye Hospital, Tianjin, Tianjin,China

Key details

Phase

Early testing / Safety & dosing

Sponsor

Frontera Therapeutics

Collaborators

Tianjin Medical University Eye Hospital, The First Affiliated Hospital of Soochow University

Enrollment target

~78 participants

Started

August 2023

Primary completion

October 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

50 Years – 80 Years

Last updated July 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.